Christine Cassiano | Chief Communications Officer |
David Chang | President and Chief Executive Officer |
Rafael Amado | Executive Vice President of Research and Development and Chief Medical Officer |
Eric Schmidt | Chief Financial Officer |
Biren Amin | Jefferies & Company, Inc. |
Philip Nadeau | Cowen and Company |
Tyler Van Buren | Piper Jaffray |
Amanda Murphy | BTIG, LLC |
Mark Breidenbach | Oppenheimer & Co. Inc. |
Raju Prasad | William Blair & Company |
John Newman | Canaccord Genuity Group Inc. |
Kelsey Goodwin | Guggenheim Securities |
Benjamin Burnett | Stifel Financial Corp. |
Charles Butler | ROTH Capital Partners |
Good morning, ladies and gentlemen, and thank you for standing by. And welcome to Allogene Therapeutics Third Quarter 2019 Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised today’s conference will be recorded.